Ankylosing spondylitis

From Citizendium
Jump to navigation Jump to search
This article is developing and not approved.
Main Article
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
This editable Main Article is under development and subject to a disclaimer.

In medicine and rheumatology, ankylosing spondylitis is an "inflammatory joint disease affecting the spine. It occurs predominantly in young males and produces pain and stiffness as a result of inflammation of the sacroiliac, intervertebral, and costovertebral joints. Etiology is unknown."[1][2]


Inhibitors of tumor necrosis factor-alpha can benefit according to a meta-analysis.[3] For example, TNFR-Fc fusion protein (etanercept - pronounced et a ner' set) blocks the activity of tumor necrosis factor-alpha.[4] and may help patients with ankylosing spondylitis.[5][6]


  1. Anonymous (2022), Ankylosing spondylitis (English). Medical Subject Headings. U.S. National Library of Medicine.
  2. Braun J, Sieper J (April 2007). "Ankylosing spondylitis". Lancet 369 (9570): 1379–90. DOI:10.1016/S0140-6736(07)60635-7. PMID 17448825. Research Blogging.
  3. McLeod C, Bagust A, Boland A, et al (August 2007). "Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation". Health Technol Assess 11 (28): 1–158, iii–iv. PMID 17651658. [e]
  4. The most up-to-date information about Etanercept and other drugs can be found at the following sites.
  5. Gorman JD, Sack KE, Davis JC (May 2002). "Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha". N. Engl. J. Med. 346 (18): 1349–56. DOI:10.1056/NEJMoa012664. PMID 11986408. Research Blogging.
  6. Furst DE, Breedveld FC, Kalden JR, et al (November 2007). "Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007". Ann. Rheum. Dis. 66 Suppl 3: iii2–22. DOI:10.1136/ard.2007.081430. PMID 17934088. Research Blogging.